rais pt transform
rais pt reiter
overweight rate upjohn transact yield
lower financi leverag attract dividend yield
rais pt ev old ebitda ev newco
ebitda newco calcul follow estim ev
pro forma ebitda net debt
yield equiti valu share price base share count
deal result share newco exhibit assum
deal complet one share essenti one newco upjohn
share one share today equat one remainco
innov newco today share
expect benefit multipl expans due three key posit
upjohn deal greater global scale strength upjohn bring
togeth complementari franchis geographi capabl lower
leverag stand-alone debt ebitda newco pro-forma
management target attract div yield
deriv newco gener dividend
impli least dividend payment improv corpor
govern newco us base domicil essenti free dutch
sticht recent highlight dutch sticht constrain factor
valuat see may report dutch sticht report
need visibl newco upjohn revenu growth
prospect base current stand-alone model includ
compound-annual-growth-rate stand-alone upjohn yield
combin newco
 unit state america
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
pt base newco ebitda estim ev
pro forma ebitda net debt
yield equiti valu share price base
share count
earn cost synergi upsid drive ebitda expect price fix
resolv ev/ebitda expand improv investor percept lower
improv price trend eas competit pressur cost synergi upsid
drive upsid ebitda us price fix litig resolv minor
neg impact
ev/bas case ebitda
ev/bas case ebitda
return modest earn growth share benefit multipl
expans due upjohn transact posit expect modest ebitda
growth base part driven cost synergi make
progress de-lever balanc sheet
ev/bear case ev/ebitda
ev/bear case ev/ebitda
financi wors expect due sever competit pressur
share price pressur worsen new product launch fall short
expect upjohn transact econom disappoint yield ebitda
forecast us price fix litig caus signific financi oper
and/or management penalti opioid litig fear rise despit lack
exposur brand opioid promot ev/ebitda multipl contract
rate overweight
expect factor lower leverag
attract dividend yield improv
corpor govern help boost
multipl multi-year low level
ebitda base
expect continu make
progress toward de-lever balanc
view opioid litig minor
risk brand
price trend competit landscap
financi momentum rel
financi result guidanc updat
success new product launch
resolut gener industri price
risk achiev price
busi could disappoint due
new launch contribut may fall short
expect due increas competit
facil issu could problemat
involv may result fine claim
execut wrongdo note presid rajiv
malik mention certain press
report investig
exhibit reconcili pfe/myl share newco calcul
consist notion share today remainco share share newco
current mylan share million
current share million
share
exhibit valuat newco upjohn
newco share count see share count calc
thomson reuter us gener peer group compris teva
thomson reuter us gener peer group compris teva
exhibit us specialti brand gener comp sheet
us specialti brand gener
price
price
spec brand gx mean
spec brand gx median
sg sale
 sale
short-term invest
a/p accru liabil
total liabil s/e
chang work capit
oper
invest
net chang debt
financ
net chang cash
